Introduction {#sec1}
============

Discovery of new compounds to treat human disease is a multifaceted process involving the selection of chemicals with favorable pharmacological properties: a high potency to the desired target, elimination or minimization of safety liabilities, and a favorable pharmacokinetic (PK) profile. To address this challenge, the drug discoverer has a wealth of choices, with total "drug-like" chemical matter estimated between 10^22^ and 10^60^ unique molecules. However, evaluating the desirability of these molecules with respect to potency, pharmacokinetics, and safety liabilities is a time-consuming and expensive process. Many of these molecules require *de novo* synthesis, which is a rate-limiting step. Furthermore, evaluation of pharmacological properties both *in vitro* and especially *in vivo* is prohibitively expensive given the universe of possible choices.

To aid in this design challenge, the field of computer-aided drug design has evolved to rapidly predict the properties of pharmacological matter *in silico*, allowing for rational selection of a feasible set of compounds for synthesis and evaluation. These techniques generally fall into two categories: (1) structure-based drug design, which relies on knowledge of the target structure (i.e., docking, molecular dynamics, free energy perturbation), and (2) ligand-based drug design, which uses known properties of molecules to develop models of quantitative structure--activity relationships (QSAR).

Ligand-based drug design generally relies on machine learning-based techniques to identify the link between structure and the property of interest. Recently, a proliferation of advanced machine learning techniques have shown great promise in increasing the predictability of QSAR models. A deep learning model first won the Merck Kaggle multiactivity challenge in 2014,^[@ref1]^ and since then these models have continued to show increased predictive accuracy over QSAR models based on classical machine learning techniques in many studies.^[@ref2]^ A recent example of success with deep learning is the paper by Feinberg et al. that compared the PotentialNet deep learning method with existing shallow learners on a wide array of pharmaceutically relevant data sets.^[@ref3]^ These results showed dramatic improvements for deep learning based on temporal splits using data collected from a pharmaceutical company. Another evaluation showed that a directed message-passing neural network model can provide robust performance over a range of experimental data sets characterizing molecular properties.^[@ref4]^ The authors provide an open-source deep learning software to go with this paper that has been tested on a wide range of parameters. However, this software does not include any type of modular pipeline that would allow for the incorporation of different models and chemical representations. Overall there has been a lack of publicly available suites of software tools that support a transparent and reproducible generation of a diverse array of deep and classical machine learning models, especially ones that can scale to model the large set of pharmaceutically relevant parameters. A major advance toward this goal was made with the introduction of DeepChem,^[@ref5]^ which supports the building of a variety of machine learning models for small molecule property prediction. DeepChem contains a variety of very helpful modules and tools, but has limitations in its ability to robustly train models from a wide selection of hyperparameters, and published performance evaluation is limited to a small number of public data sets with less diverse pharmaceutical relevance.^[@ref6]^

In this paper, we introduce a new small molecule property prediction pipeline, AMPL. This software was developed through the Accelerating Therapeutics Opportunities in Medicine (ATOM) Consortium as the ATOM Modeling PipeLine. The key contributions of this work are to automate deep learning training, particularly in hyperparameter search; to enable extensive performance benchmarking; and to apply AMPL to a large collection of pharmaceutically relevant property-prediction data sets. Most notably, AMPL is available as open source to benefit the drug discovery community.

The closest existing pipeline tools are BIOVIA Pipeline Pilot^[@ref7]^ and KNIME.^[@ref8]^ Pipeline Pilot is a license-based graphical tool for machine learning pipelining. It has capabilities for data cleaning, splitting, training, and model deployment, but are all mainly GUI-based, limiting the customizability of the software. Furthermore, it is only available for a licensing fee, so it does not target the open source community. In terms of free and open source software suites for data analytics, the main alternative is KNIME. This software provides an environment for creating general data flows to process data, use predictive models, and analyze complex data sets. An ecosystem of open source and commercial KNIME node extensions has developed which enable workflows for library analyses, virtual screening, model fitting and prediction. In contrast, AMPL is tightly focused on integrating modern machine learning methods with best practices for chemical activity and property prediction. Important issues with machine learning models, such as data set characterization, model validation, and uncertainty quantification are addressed by AMPL in automated and reproducible ways. The code suite also provides high performance computing modules for model fitting, hyperparameter optimization, and predictions. AMPL currently targets job submission-based clusters to scale training runs; however, AMPL could be adapted to operate on other scalable platforms such as Spark in the future. Furthermore, AMPL is implemented as a modular and reusable Python library to allow for easy integration with other data science software platforms.

An extensive set of experiments were conducted with AMPL, and key observations include the following:Physicochemical descriptors and deep learning-based graph representations are significantly better than traditional fingerprints to characterize molecular features.Data set size is directly correlated to performance of prediction: single-task deep learming models only outperform shallow learners if there is enough data. Likewise, data set size has a direct impact on model predictivity independently of comprehensive hyperparameter model tuning. Our findings point to the need for public data set integration or multi- task/transfer learning approaches.DeepChem uncertainty quantification (UQ) analysis may help identify model error; however, efficacy of UQ to filter predictions varies considerably between data sets and model types.

The aim of this paper is to present the rigorous and transparent open source software pipeline AMPL to build global and local 'baseline' models for a wide array of molecular properties that are needed for *in silico* drug discovery. This new software will support reproducible training and testing protocols that enable the broader modeling community to evaluate and improve modeling approaches over time.

Methods {#sec2}
=======

[Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} shows the overall architecture of AMPL. This end-to-end pipeline supports all functions needed to generate, evaluate, and save machine learning models: data ingestion and curation, featurization of chemical structures into feature vectors, training and tuning of models, storage of serialized models and metadata, and visualization and analysis of results. It also contains modules for parallelized hyperparameter search on high-performance computing (HPC) clusters.

![Overview of AMPL.](ci9b01053_0001){#fig1}

Data Curation {#sec2.1}
-------------

AMPL includes several modules to curate data into machine learning-ready data sets. Functions are provided to represent small molecules with canonicalized SMILES strings using RDKit^[@ref9]^ and the MolVS package,^[@ref10]^ by default stripping salts and preserving isomeric forms. Data curation procedures are provided with AMPL as Jupyter notebooks,^[@ref11]^ which can be used as examples for curating new data sets. Procedures allow for averaging response values for compounds with replicate measurements and filtering compounds with high variability in their measured response values. AMPL also provides functions to assess the structural diversity of the data set, using either Tanimoto distances between fingerprints or Euclidean distances between descriptor feature vectors.

Data ingestion and curation-related parameters include the following:Unique human readable name for training fileData privilege access groupParameter for overriding the output files/data set object namesID for the metadata + data setBoolean flag for using an input file from the file systemName of column containing compound IDsName of column containing SMILES stringsList of prediction task namesNumber of classes for classificationUser specified list of names of each classBoolean switch for using transformation on regression output. Default is TrueResponse column normalization typeMinimum number of data set compounds considered adequate for model training. A warning message will be issued if the data set size is less than this.

Featurization {#sec2.2}
-------------

AMPL provides an extensible featurization module that can generate a variety of molecular feature types, given SMILES strings as input. They include the following:Extended connectivity fingerprints (ECFP) with arbitrary radius and bit vector length^[@ref12]^Graph convolution latent vectors, as implemented in DeepChem^[@ref13]^Chemical descriptors generated by the Mordred open source package^[@ref14]^Descriptors generated by the commercial software package Molecular Operating Environment (MOE)^[@ref15]^User-defined custom feature classes

Because some types of features are expensive to compute, AMPL supports two kinds of interaction with external featurizers: a dynamic mode in which features are computed on-the-fly and a persistent mode whereby features are read from precomputed tables and matched by compound ID or SMILES string. In the persistent mode, when SMILES strings are available as inputs, the featurization module matches them against the precomputed features where possible and computes features dynamically for the remainder. Because precomputed feature tables may span hundreds or thousands of feature columns for millions of compounds, the module uses the feather format^[@ref16]^ to speed up access.

Featurized data sets for feature types that support persistent mode (currently, all except ECFP fingerprints and graph convolution format) are saved in the filesystem or remote datastore, so that multiple models can be trained on the same data set. This also facilitates reproducibility of model results.

Chemical descriptor sets such as those generated by MOE often contain descriptors that are exact duplicates or simple functions of other descriptors. In addition, large blocks of descriptors may be strongly correlated with one another, often because they scale with the size of the molecule. The featurization module deals with this redundancy by providing an option to remove duplicate descriptors and to scale a subset of descriptors by the number of atoms in the molecule (while preserving the atom count as a distinct feature). Factoring out the size dependency often leads to better predictivity of models.

The featurization module can be easily extended to handle descriptors generated by other software packages, latent vectors generated by autoencoders, and other types of chemical fingerprints. In most cases, this can be accomplished by writing a small function to invoke the external feature generation software, and by adding an entry to a table of descriptor types, listing the generated feature columns to be used. In more complicated cases, one may need to write a custom subclass of one of the base featurization classes.

Featurization-relevant input parameters include the following:Type of molecule featurizerFeature matrix normalization typeBoolean flag for loading in previously featurized data filesType of transformation for the featuresRadius used for ECFP generationSize of ECFP bit vectorsType of autoencoder, e.g., molvae, jtTrained model HDF5 file path, only needed for MolVAE featurizerType of descriptors, e.g., MOE, MordredMaximum number of CPUs to use for Mordred descriptor computations. None means use all available.Base of key for descriptor table file

Data Set Partitioning {#sec2.3}
---------------------

AMPL supports several options for partitioning data sets for model training and evaluation. By default, splitting follows an approach similar to nested cluster-cross-validation.^[@ref17]^ Data sets are divided into three nonoverlapping bins: (1) training, (2) model selection (validation), and (3) performance evaluation (test). Nested cluster-cross-validation uses single-linkage clustering and Jaccard distance from ECFP4 fingerprints. This option is available in AMPL as the "fingerprint" splitter. The results reported here are based on a different clustering method, which clusters molecules by shared scaffolds using the Bemis--Murcko definition. Both methods show similar reduced prediction accuracy when compared to randomly separating molecules into one of the three nonoverlapping bins. Alternatively, AMPL offers a *k*-fold cross-validation option, to assess the performance impact of sampling from the modeled data set. Under *k*-fold cross-validation, the holdout test set is selected first, and the remainder is divided into *k*-fold sets for training and validation.

AMPL offers a number of data set splitting algorithms, which offer different approaches to the problem of building models that generalize from training data to novel chemical space. It supports several of the methods included in DeepChem, including random splits, Butina clustering, Bemis--Murcko scaffold splitting, and the algorithm based on fingerprint dissimilarity.^[@ref6]^ In addition, we implemented temporal splitting and a modified version of the asymmetric validation embedding (AVE) debiasing algorithm.^[@ref18]^ We compared random splitting with Bemis--Murcko scaffold splitting for our benchmarking experiments.

Input parameters related to data splitting include the following:Type of splitter to use: index, random, scaffold, Butina, ave_min, temporal, fingerprint, or stratifiedBoolean flag for loading in previously split train, validation, and test CSV filesUUID for CSV file containing train, validation, and test split informationChoice of splitting type between *k*-fold cross validation and a normal train/valid/test splitNumber of *k*-folds to use in *k*-fold cross validationType of splitter to use for train/validation split if temporal split used for test set (random, scaffold, or ave_min)Cutoff Tanimoto similarity for clustering in Butina splitterCutoff date for test set compounds in temporal splitterColumn in data set containing dates for temporal splitterFraction of data to put in validation set for train/valid/test split strategyFraction of data to put in held-out test set for train/valid/test split strategy

Model Training and Tuning {#sec2.4}
-------------------------

AMPL includes a train/tune/predict framework to create high-quality models. This framework supports a variety of model types from two main libraries: scikit-learn^[@ref19]^ and DeepChem 2.1.0.^[@ref5]^ Currently, specific input parameters are supported for the following:Random forest models from scikit-learnXGBoost models^[@ref20]^Fully connected neural network modelsGraph convolution neural network models^[@ref21]^As with the featurization module, AMPL supports integration of custom model subclasses. Parameters for additional models can be easily added to the parameter parser module.

Model-relevant input parameters include the following:Type of model to fit (neural network, random forest, or xgboost)Prediction type (regression or classification)Singletask or multitask modelNumber of decision trees in the forest for random forest modelsMaximum number of features to split random forest nodesNumber of estimators to use in random forest modelsBatch size for neural network modelOptimizer type for neural network modelOptimizer specific for graph convolutional models, defaults to "adam"Model batch size for neural network modelList of hidden layer sizes for neural network modelList of dropout rates per layer neural network modelList of standard deviations per layer for initializing weights for neural network modelThe type of penalty to use for weight decay, either "l1" or "l2"The magnitude of the weight decay penalty to useList of initial bias parameters per layer for neural network modelLearning rate for dense neural network modelsEpoch for evaluating baseline neural network model performance, if desiredMaximum number of training epochs for neural network modelType of score function used to choose best epoch and/or hyperparametersBoolean flag for computing uncertainty estimates for regression model predictions

### Epoch Selection for Neural Net Models {#sec2.4.1}

Early stopping is an essential strategy to avoid overfitting of neural networks; thus, the number of training epochs is one of the key hyperparameters that must be optimized. To implement early stopping, AMPL trains neural network models for a user-specified maximum number of epochs, evaluating the model on the validation set after each epoch, and identifies the epoch at which a specified performance metric is maximized. By default, this metric is the coefficient of determination *R*^2^ for regression models and the area under the receiver operating characteristic curve (ROC AUC) for classification models.

### Model Persistence {#sec2.4.2}

Serialized models are saved after training and prediction generation are complete, along with detailed metadata to describe the model. This supports traceability and reproducibility, as well as model sharing. AMPL supports saving models and results either using the file system or optionally through a collection of database services. The metadata can be stored in a mongoDB database^[@ref22]^ or as JSON files. AMPL has functions for saving models and loading prebuilt models for prediction generation.

Model Performance Metrics {#sec2.5}
-------------------------

AMPL calculates a variety of performance metrics for predictions on the training, validation and test sets. Metrics may be saved in a mongoDB database or in JSON files. For regression models, we calculate the following:Coefficient of determination (*R*^2^). This is calculated using sklearn's metrics function. Note that this score can be negative if the model is arbitrarily worse than random.Mean absolute error (MAE). An advantage of MAE is that it has a clear interpretation, the average absolute difference between the measured value *y*~*i*~ and predicted value *ŷ*~*i*~. This works well for cellular activity assay data sets, which use log normalized dose concentration value with similar concentration ranges across different assays. PK parameters are measured on different scales for some assays, which prevents comparison between assays with this metric.Mean square error (MSE). This is a risk metric corresponding to the expected value of the squared error (or loss).

For classification models, we calculate the following:Area under the receiver operating characteristics curve (ROC AUC). The ROC curve plots the true positive rate versus the false positive rate as a binary classifier's discrimination threshold is varied. The ROC AUC score is calculated by finding the area under the ROC curve. This value can range from 0--1, where 1 is the best score.Precision (positive predictive value)where TP = number of true positives and FP = number of false positivesRecall (true positive rate/sensitivity)where TP = number of true positives and TN = number of true negatives.Area under the precision-recall curve (PRC-AUC). The precision-recall curve plots precision versus recall as a binary classifier's discrimination threshold is varied. It is a good measure of success of prediction when classes are very imbalanced. High scores show that the classifier is returning accurate results (high precision), as well as returning a majority of all positive results (high recall).Negative predictive value (NPV)where TN = number of true negatives and FN = number of false negativesCross entropy (log loss)Accuracywhere terms are defined as above.

Uncertainty Quantification {#sec2.6}
--------------------------

Uncertainty quantification (UQ) attempts to measure confidence in a model's prediction accuracy by characterizing variance in model predictions. Some common objectives for UQ are to use it to guide active learning or to weight model ensembles. AMPL generates UQ values for both random forest and neural network models.

### Uncertainty Quantification for Random Forest {#sec2.6.1}

Generating a value quantifying uncertainty is straightforward for random forest and is taken to be the standard deviation of predictions from individual trees. This quantifies how variable these predictions are and thus how uncertain the model is in its prediction for a given sample.

### Uncertainty Quantification for Neural Networks {#sec2.6.2}

Our neural network-based UQ uses the Kendall and Gal method^[@ref23]^ as implemented in DeepChem 2.1.0. This method combines aleatoric and epistemic uncertainty values to compute an estimate of the overall model error:

Aleatoric uncertainty, which is the inherent noise in the data, cannot be reduced by adding more data, but it can be estimated. The aleatoric uncertainty can be predicted concurrently with the response variable by modifying the loss function of the model to include a term for the observation noise.

Epistemic uncertainty, the uncertainty over the model parameters, arises because of limited data. Normally, this is calculated in a bootstrapped manner, as in the case of a random forest. For models that are expensive to train, such as neural networks, we instead train one network to generate a set of predictions by applying a set of dropout masks during prediction. Prediction variability is then quantified to assess epistemic uncertainty.

Visualization and Analysis {#sec2.7}
--------------------------

Plots generated by AMPL's visualization and analysis module are shown in the [Results](#sec3){ref-type="other"}. Additional options include plots of predicted vs actual values, learning curves, ROC curves, precision vs recall curves, and 2-D projections of feature vectors using UMAP.^[@ref24]^ The module also includes functions for characterizing and visualizing chemical diversity. Chemical diversity analysis is crucial for analyzing domain of applicability, bias in data set splitting, and novelty of *de novo* compounds. This module supports a wide range of input feature types, distance metrics, and clustering methods.

Hyperparameter Optimization {#sec2.8}
---------------------------

A module is available to support distributed hyperparameter search for HPC clusters. This module currently supports linear grid, logistic grid, and random hyperparameter searches, as well as iteration over user-specified values. To run the hyperparameter search, the user specifies the desired range of configurations in a JSON file. The user can either specify a single data set file or a CSV file with a list of data sets. The script generates all valid combinations of the specified hyperparameters, accounting for model and featurization type, and submits jobs for each combination to the HPC job scheduler. The module includes an option to generate a prefeaturized and presplit data set before launching the model training runs, so that all runs operate on the same data set split. The user can specify a list of layer sizes and dropouts to combine, along with the maximum final layer size and a list of the numbers of possible layers for a given model, and the module combines these different options based on the input constraints to generate a variety of model architectures. The search module can check the model tracker database to avoid retraining models that are already available. It also provides users the option to exclude hyperparameter combinations that lead to overparameterized models, by checking the number of weight and bias parameters for a proposed neural network architecture against the size of the training data set. Finally, the search module throttles job submissions to prevent the user from monopolizing the HPC cluster.

Input parameters for hyperparameter search include the following:Boolean flag indicating whether we are running the hyperparameter search scriptUUID of hyperparam search run model was generated inComma-separated list of number of layers for permutation of NN layersComma-separated list of dropout rates for permutation of neural network layersThe maximum number of nodes in the last layerComma-separated list of number of nodes per layer for permutation of neural network layersMaximum number of jobs to be in the queue at one time for an HPC clusterScaling factor for constraining network size based on number of parameters in the networkBoolean flag directing whether to check model tracker to see if a model with that particular param combination has already been builtPath where pipeline file you want to run hyperparam search from is locatedType of hyperparameter search to do. Options are grid, random, geometric, and user_specified/CSV file containing list of data sets of interest

Running AMPL {#sec2.9}
------------

There are three ways to run AMPL:Using a config file: Create a JSON file with desired model parameters and run full pipeline via command line.Using command line arguments: Specify model parameters via standard command line arguments.Interactively in a Jupyter notebook using an argparse.Namespace object or a dictionary

Results {#sec3}
=======

Benchmark experiments were run to evaluate and validate components of the pipeline.

Data {#sec3.1}
----

Experimental data sets were made available by ATOM Consortium member GlaxoSmithKline from a variety of bioactivity and pharmacokinetics experiments. Selected data sets were used for training and evaluating models. These data sets are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

###### Pharmacokinetics Datasets Used to Benchmark AMPL

  data set                       units                   species   data set size   minimum   maximum   mean    median
  ------------------------------ ----------------------- --------- --------------- --------- --------- ------- --------
  blood to plasma ratio                                  human     101             0.47      10.5      0.85    0.77
  blood to plasma ratio                                  dog       71              0.37      6.85      0.85    0.88
  plasma protein binding HSA     fraction unbound        human     123734          0.0001    1         0.05    0.044
  plasma protein binding HSA     fraction unbound        rat       2086            0.0001    1         0.036   0.033
  plasma clearance (*in vivo*)   mL/min/kg               dog       1181            0.1       2946      12.6    15.2
  plasma clearance (*in vivo*)   mL/min/kg               rat       10431           0.001     8763      30.2    38.2
  Vd,ss                          L/kg                    dog       1054            0.07      569       1.9     1.9
  Vd,ss                          L/kg                    rat       9681            0.01      2080      2.3     2.4
  hepatocyte clearance           mL/min/g liver tissue   human     1695            0.01      97        1.6     1.5
  hepatocyte clearance           mL/min/g liver tissue   dog       630             0.1       504       2       1.8
  hepatocyte clearance           mL/min/g liver tissue   rat       2098            0.02      878       2.9     2.9
  microsomal clearance           mL/min/g liver tissue   human     29162           0         156       2.8     2.4
  microsomal clearance           mL/min/g liver tissue   dog       2080            0.03      150       2.5     1.8
  microsomal clearance           mL/min/g liver tissue   rat       30563           0.01      198       3.9     3.7
  log *D*                                                          27345           0.01      53703     258     407

Pharmacokinetic (PK) and safety data sets ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) were curated separately, as they contain different types of experimental data and thus require different processing. The raw data sets were cleaned to remove rows with outlying, missing, and duplicate measurements, and processed to yield machine learning data sets with a single aggregate value per unique compound. These procedures informed the design of curation functions included in the pipeline. Curation of the PK data sets required the conversion of values to standard units, the removal of compounds with stability or recovery issues, and the exclusion of data that was generated using significantly different assay protocols. Subsequently, replicate experimental measurements were identified by matching duplicate canonical SMILES strings and averaged to produce a single value per compound.

###### Safety Datasets Used to Benchmark AMPL

  assay                       target                                          primary liability   experimental system      detection                       compounds
  --------------------------- ----------------------------------------------- ------------------- ------------------------ ------------------------------- -----------
  BSEP pIC50                  Bile Salt Export Pump                           hepatic             membrane vesicles                                        187
  ADRA1B pIC50                adrenergic a1B pIC50                            CNS                 intracell Ca                                             3537
  ADRA2C pIC50                a2C adrenoceptor                                CNS                 CHO K1                                                   2873
  ADRB2 pEC50                 2 adrenoceptor                                  CNS                 FRET                                                     2815
  CHRM1 pEC50                 cholinergic receptor muscarinic 1               CNS                 CHO                      intracellular Ca fluorescence   5315
  CHRM1 pIC50                 cholinergic receptor muscarinic 1               CNS                 CHO                      intracellular Ca fluorescence   4547
  CHRM2 pEC50                 cholinergic receptor muscarinic 2               CNS                 CHO                      intracellular Ca fluorescence   4742
  DRD2 pEC50                  dopamine D2                                     CNS                 HEK293F low Na GTPgS     SPA                             14450
  GRIN1 pIC50                 GRIN1 GRIN2B NR2B NR1A 2B subunit pIC50         CNS                                                                          2663
  HRH1 pIC50                  histamine receptor H1                           CNS                                          luminescence                    7971
  HTR1B pIC50                 5-hydroxytryptamine receptor 1B                 CNS                 10 μL LEADseeker GTPgS                                   6300
  HTR2A pEC50                 5-hydroxytryptamine receptor 2A                 CNS                 HEK                      luminescence                    4259
  HTR2A pIC50                 5-hydroxytryptamine receptor 2A                 CNS                 HEK                      luminescence                    4250
  HTR2C pEC50                 5-hydroxytryptamine receptor 2C                 CNS                 CHO                      luminescence                    2938
  HTR2C pIC50                 5-hydroxytryptamine receptor 2C                 CNS                 CHO                      luminescence                    2939
  HTR3A pIC50                 5-hydroxytryptamine receptor 3A                 CNS                 FLIPR                                                    6645
  KCNA5 (Kv1.5) pIC50         KCNA5 (Kv1.5)                                   cardiovascular      CHO                      electrophys                     4178
  KCNE1 KCNQ1 (Kv7.1) pIC50   KCNE1 KCNQ1 (Kv7.1)                             Cardiovascular      MinK human blocker CHO   electrophys                     2373
  MAOA pIC50                  monoamine oxidase A                             CNS                                          FLINT                           344
  PDE3A pIC50                 phosphodiesterase 3A                            Cardiac                                      SPA (cAMP inhibition)           614
  PDE4B pIC50                 phosphodiesterase 4B                            CNS                                          SPA                             564
  Phospholipidosid pEC50      phospholipidosis induction                      cellular tox        HEPG2                    FLINT                           278
  PI3K pIC50                  phosphoinositide 3-kinase (pI3K)                cellular tox                                 TR FRET                         9173
  COX 2 pIC50                 cyclooxygenase 2                                cardiovascular                               FLINT SAR                       3865
  SCN5A (NaV1.5) pIC50        SCN5A (NaV1.5)                                  cardiovascular                                                               3577
  SCL6A2 pIC50                noradrenaline Transporter NET                   CNS                                          BacMam bind SPA                 2805
  SLC6A4 pIC50                seratonin Transporter (SERT)                    CNS                                          BacMam binding SPA              3520
  OATP1B1 pIC50               organic anion transport polypeptide (SLCO1B1)   hepatic             HEK                      image                           1789

For the safety data sets, censored measurements were an additional concern. Since bioactivity assays are typically performed over a limited range of compound concentrations, IC50 or EC50 values may be reported as being above or below a maximum or minimum concentration, so that the measurements are censored. When all measurements for a compound are censored in the same direction, the user is given the option to either exclude the compound from the data set, or include it with a relational operator indicating the direction together with the censoring threshold. In the case where some replicate measurements are censored and some are not, AMPL computes a maximum likelihood estimate for the mean activity, assuming a Gaussian distribution of measurements around the true mean. The distribution of response values is reported along with the mean and standard deviation.

Experimental Design for Regression Pharmacokinetic Models {#sec3.2}
---------------------------------------------------------

To evaluate AMPL's performance, we built a total of 11,552 models on 15 pharmacokinetic data sets and 26 bioactivity data sets. These models include 9422 regression models and 2,130 classification models. The data sets are proprietary and were not released; however, public data sets are included in the supplemental.

We evaluated a variety of deep learning model types and architectures and compared them to baseline random forest models. We explored the performance of four types of features: ECFP fingerprints, MOE descriptors, Mordred descriptors, and graph convolution-based latent vectors. We used the RDKit^[@ref25]^ implementation of ECFP, which is defined there as roughly equivalent to the Morgan fingerprint. Each data set was divided into a 70% (train), 10% (validation), 20% (test) split. For the neural network models, we searched over many combinations of learning rates, numbers of layers, and nodes per layer. For each combination of neural network hyperparameters, we trained for up to 500 epochs and used a validation set performance metric (*R*^2^ for regression, ROCAUC for classification) to choose an early stopping epoch for the final model. For random forest models, the only hyperparameter varied was the maximum tree depth, as previous experiments showed that other model hyperparameters had a minimal effect for our data sets. The complete set of hyperparameters that were varied is as follows:Splitter Types: scaffold and randomFeature types: ECFP, MOE, mordred, and graph convolutionModel types: neural network and random forestNeural network learning rates: 0.0001, 0.00032, 0.001, 0.0032, 0.01Maximum number of epochs: 500Number of layers: 1, 2Layer size options: 1024, 256, 128, 64, 32, 16, 8, 4, 1Dropout rate: 0.1, 0.2, 0.4

Analysis of Modeling Performance {#sec3.3}
--------------------------------

To identify which featurization type generated the most predictive models for each model type, models with the largest validation set *R*^2^ score were selected for each model/splitter/data set combination. The number of "best" models for which each feature type yielded the highest test set *R*^2^ score (also known as the holdout set) is plotted in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} shows that the chemical descriptors generated by the commercial MOE software outperformed those produced by the open source Mordred package in most cases. DeepChem's graph convolution networks outperform all other feature types for neural network models.

![Number of times each featurization type produces the best model for the 15 PK data sets](ci9b01053_0012){#fig2}

The model/featurization combination with the most accurate predictions on the holdout set is shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. MOE featurization with random forest models most frequently outperformed other featurization/model type combinations for both types of splitters.

![Number of times each featurization type/model type combination produces the best model for the 15 PK data sets.](ci9b01053_0015){#fig3}

[Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} confirms that random forest models tend to outperform neural network models for the evaluated data sets.

![Number of times each model type produces the best model for the 15 PK data sets](ci9b01053_0016){#fig4}

Investigation into Neural Network Performance {#sec3.4}
---------------------------------------------

Neural networks are known to perform more poorly on smaller data sets, so we wanted to examine the relationship between the size of a data set and the test set *R*^2^ values for the best random forest and neural network models for that data set. We chose the best model from our hyperparameter search using the validation set, but we present the test set *R*^2^ values as our final evaluation of model performance. The purpose of this 2-step process is to present a less biased evaluation of our models. When *R*^2^ values from multiple models evaluated on a single data set are similar, the models are taken to be equal in performance. [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} shows the test set *R*^2^ values for the best neural network and random forest models for each data set. The figure shows that as the data set size increases, the *R*^2^ score for the test set increases as well. The pattern is true for the overall best model, regardless of type, for both regression and classification, as shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}. These results indicate that we will need to augment our data sets to further improve model performance. We plan to explore multiple avenues to address this requirement: conducting additional experiments, running simulations, sourcing public data, building multitask models, and experimenting with transfer learning approaches.

![Plot of best model test set *R*^2^ values versus the data set size for neural network and random forest models.](ci9b01053_0017){#fig5}

![Per data set model accuracy versus data set size.](ci9b01053_0018){#fig6}

We also examined the architectures that yielded the best model for each feature type for the neural network models. Our hypothesis was that larger data sets would perform better with larger networks. The number of hidden layer parameters for the 2-layer networks was calculated by multiplying the first and second layers together. [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} shows the number of parameters in the hidden layers of the model versus the size of the data set. The color indicates the data set and the shape indicates the featurizer type. We can see a clear lower bound in the number of parameters for the best network for all featurizer types as the data set size increases.

![Number of hidden layer parameters versus number of samples for the best model for each data set/featurizer combination.](ci9b01053_0019){#fig7}

Summary of Model Performance {#sec3.5}
----------------------------

[Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"} and [Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"} show the full set of test set *R*^2^ values for the best model for each molecular featurization representation and model type for random and scaffold splits respectively (picked as before by the largest validation set *R*^2^ value). Random sampling inflates the *R*^2^ values of the holdout set, which is as expected since there is greater structural overlap between the set of compounds in the training and holdout set. For scaffold split-generated holdout sets, there is a very clear pattern between data set size and *R*^2^ value, although the complexity of the predicted property and quality of the data set also obviously has an effect.

![Performance accuracy for regression for random split.](ci9b01053_0020){#fig8}

![Performance accuracy for regression for scaffold split.](ci9b01053_0021){#fig9}

Model Tuning Results {#sec3.6}
--------------------

To evaluate whether hyperparameter search improves model performance, the test set *R*^2^ for a baseline model was compared with the test set *R*^2^ from the best-performing model selected by looking at the validation set *R*^2^ value. The distribution of improvement in test set *R*^2^ categorized by featurizer type is shown in [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}. Small data sets and ECFP-based models, which showed poor neural network performance overall, showed little to no improvement, while better-performing data sets and featurizers showed greater improvement with hyperparameter search. This suggests that data augmentation will be necessary to improve prediction performance on the smaller problematic data sets, and that ECFP is a poor featurizer no matter the hyperparameters.

![Histogram of improvement in *R*^2^ values for the test set for the four featurizers for neural network models.](ci9b01053_0002){#fig10}

Classification Experiments {#sec3.7}
--------------------------

A set of classification model experiments were also conducted for a panel of 28 bioactivity data sets, without any hyperparameter tuning. In total 2,130 neural network and random forest models were generated. A dose concentration threshold was used to label active and inactive compounds on a per-data set basis using thresholds provided by domain experts at GlaxoSmithKline. The classes were extremely unbalanced, which partially explains the high ROC-AUC scores shown in [Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}.

![Performance accuracy for classification](ci9b01053_0003){#fig11}

Uncertainty Quantification {#sec3.8}
--------------------------

To explore the utility of the uncertainty quantification values produced by neural network and random forest models, a case study is presented for three representative PK parameter data sets: rat plasma clearance (*in vivo*), human microsomal clearance, and human plasma protein binding HSA. These data sets were selected to represent small, medium, and large sized data sets with low, medium, and high *R*^2^ values.

### Precision-Recall Plot Analysis {#sec3.8.1}

Precision-recall curves measure the fraction of low error predictions made at varying UQ thresholds. Precision is defined as the fraction of predictions with UQ values less than the UQ threshold, with error less than some predefined threshold. For this analysis we use mean logged error and define "low-error" as samples with logged error below the mean (log served to normalize the distribution). Recall reports the fraction of low-error samples which pass the UQ filter threshold. Overall, we would like to use the UQ value as a threshold to identify low error samples at a higher rate than in the overall test set. [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} shows the percentage of low error samples in the test set as a whole for each data set/model/featurizer combination.

###### Percent of Total Low-Error Samples in the Test Set for the Specified Dataset, Model/Featurizer Combinations

  data set                           model and featurizer type    percent of total low error samples
  ---------------------------------- ---------------------------- ------------------------------------
  rat plasma clearance (*in vivo*)   neural network + ECFP        41.4
  rat plasma clearance (*in vivo*)   neural network + GraphConv   41.8
  rat plasma clearance (*in vivo*)   neural network + MOE         42.9
  rat plasma clearance (*in vivo*)   neural network + Mordred     40.5
  rat plasma clearance (*in vivo*)   random forest + ECFP         42.5
  rat plasma clearance (*in vivo*)   random forest + MOE          41.7
  rat plasma clearance (*in vivo*)   random forest + Mordred      42.0
  human microsomal clearance         neural network + ECFP        41.0
  human microsomal clearance         neural network + GraphConv   41.0
  human microsomal clearance         neural network + MOE         39.0
  human microsomal clearance         neural network + Mordred     39.8
  human microsomal clearance         random forest + ECFP         39.5
  human microsomal clearance         random forest + MOE          38.5
  human microsomal clearance         random forest + Mordred      39.6
  human plasma protein binding HSA   neural network + ECFP        43.4
  human plasma protein binding HSA   neural network + GraphConv   43.0
  human plasma protein binding HSA   neural network + MOE         43.1
  human plasma protein binding HSA   neural network + Mordred     43.5
  human plasma protein binding HSA   random forest + ECFP         42.0
  human plasma protein binding HSA   random forest + MOE          42.8
  human plasma protein binding HSA   random forest + Mordred      42.5

In general, a low UQ threshold with accurate uncertainty would correspond to a precision of 1, which means confident predictions correspond to low-error predictions. To have the greatest utility, the curve should keep fairly high precision as the recall increases. UQ successfully filters out low confidence predictions in some cases but performance varies widely with the model/featurization type and the data set. [Figures [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"},[13](#fig13){ref-type="fig"}, and [14](#fig14){ref-type="fig"} show that precision drops quickly as recall increases, and for some models precision is poor even when applying the lowest UQ threshold. Nevertheless, for each data set there exists a UQ threshold for at least one model which could be used to increase the fraction of low error predictions over the baseline percentages shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. For example, [Figure [14](#fig14){ref-type="fig"}](#fig14){ref-type="fig"} suggests that applying a UQ threshold could increase precision to 65% from around 42% with a recall of 10%. Later, it is shown that for the human plasma protein binding HSA data set that this could still yield a collection of compounds with a diverse range of response values.

![Precision-recall plot for rat plasma clearance (*in vivo*), varying UQ value.](ci9b01053_0004){#fig12}

![Precision-recall plot for human microsomal clearance, varying UQ value.](ci9b01053_0005){#fig13}

![Precision-recall plot for human plasma protein binding HSA, varying UQ value](ci9b01053_0006){#fig14}

### Calibration Curves {#sec3.8.2}

To further investigate how error changes as the uncertainty increases, we plotted calibration curves of mean error per uncertainty bucket, with the 95% confidence interval of error shown for each bucket as error bars. We would like uncertainty to serve as a proxy for error, so we would hope to see the mean error for the samples in a bucket increase as the UQ threshold for that bucket increased. Calibration curves for the neural network built on MOE feature vectors and random forest models built on MOE feature vectors and neural network graph convolution models have been computed to demonstrate the variation in performance.

For rat plasma clearance (*in vivo*), there is an overall upward trend for all three calibration curves, but it is not completely monotonically increasing for any of them. [Figure [15](#fig15){ref-type="fig"}](#fig15){ref-type="fig"}, the calibration curve for the neural network model with MOE features is shown as an example (See [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf) for RF/MOE and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf) for NN/GraphConv). This is the smallest data set of our case study, so increasing the bucket size may improve the choppiness of these curves, but overall UQ does not look like it would be a reliable proxy for error for this data set.

![Mean error per uncertainty bucket for rat plasma clearance (*in vivo*) neural network model with MOE features.](ci9b01053_0007){#fig15}

Human microsomal clearance shows greater variation in the calibration curves. For MOE features with a neural network model ([Figure [16](#fig16){ref-type="fig"}](#fig16){ref-type="fig"}), shows an inverse pattern where the error actually decreases as the uncertainty increases. For MOE features with a random forest model ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)), there seems to be no correlation, except for in the very highest bucket.

![Mean error per uncertainty bucket for human microsomal clearance neural network model with MOE features.](ci9b01053_0008){#fig16}

The graph convolution model ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)), conversely, shows an upward trend, although it is not monotonically increasing. These curves show that the featurizer and model type have a strong effect on the relationship between UQ and error.

For human plasma protein binding HSA, which is the largest data set with over 123 000 compounds, all calibration curves display the desired behavior ([Figures [17](#fig17){ref-type="fig"}](#fig17){ref-type="fig"}, [S5, and S6](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)): error increases as uncertainty increases and the 95% confidence intervals are small.

![Mean error per uncertainty bucket for human plasma protein binding HSA neural network model with MOE features.](ci9b01053_0009){#fig17}

### Examining the Relationship between UQ and Predicted Value {#sec3.8.3}

Since the UQ values quantify the variation in predictions, the relationship between UQ and the predicted values were checked for evidence of a correlation by examining plotted UQ versus predicted values. Results for three model types were plotted, but only neural network models with MOE features are shown as an example (see the [Supporting Information spreadsheet](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_001.xlsx) for RF/MOE and NN/GraphConv results).

Rat plasma clearance (*in vivo*) shows a somewhat negative relationship, where the variation in predictions decreases as the magnitude of the predicted value increases. We found a similar though much less pronounced trend when examining error versus predicted value, so it looks like overall the model is predicting better for compounds with higher clearance values ([Figures [18](#fig18){ref-type="fig"}](#fig18){ref-type="fig"}, [S7, and S8](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)).

![Uncertainty value versus Predicted for rat plasma clearance (*in vivo*) neural network model with MOE features](ci9b01053_0010){#fig18}

For human microsomal clearance, MOE feature vectors yield models where the UQ is strongly biased by the predicted value, especially for the neural network model, as seen in [Figure [19](#fig19){ref-type="fig"}](#fig19){ref-type="fig"}. Error versus predicted value does not show this trend, so this is likely indicating that UQ contains no real information value for this model. This trend exists for the MOE random forest model as well ([Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)), although it levels off, suggesting slightly less biased UQ values. The graph convolution model ([Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)) displays a more balanced relationship between UQ and predicted value, which mirrors what we saw in the previous two subsections, that this model's UQ is more informative of error than the MOE models' UQ.

![Uncertainty value versus predicted value for human microsomal clearance neural network model with MOE features.](ci9b01053_0011){#fig19}

Human plasma protein binding HSA, which showed the best calibration curves, also shows the least correlation between UQ and predicted value. [Figure [20](#fig20){ref-type="fig"}](#fig20){ref-type="fig"} shows the correlation between UQ and predicted value for a human plasma protein binding HSA neural network model with MOE features ([Figures S11 and S12](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf)) show the model for random forest with MOE features and neural network with Graph Convolution features). UQ has a wide range of values for all predicted values.

![Uncertainty value versus predicted value for human plasma protein binding HSA neural network model with MOE features](ci9b01053_0013){#fig20}

### Correlation between UQ and Error {#sec3.8.4}

While these plots provide useful methods for visualizing the behavior of uncertainty quantification, we wanted to identify a value that could summarize if we could trust a given model's UQ results. Since we want the certainty of the model to be reflected in accurate predictions, we calculated the Spearman correlation coefficient between binned prediction error and UQ. Results are shown in [Figure [21](#fig21){ref-type="fig"}](#fig21){ref-type="fig"}. Correlations range from −0.088 to 0.33. While these correlations are fairly low, all *p*-values are \<0.05, and all but one are ≪0.01. There is a weak but statistically significant correlation; therefore, we conclude that UQ cannot be used to reliably predict error in the general case.

![Spearman correlation coefficient between error and uncertainty values](ci9b01053_0014){#fig21}

Discussion {#sec4}
==========

Key observations from the extensive series of model evaluations are summarized here:Neural networks generally produced more accurate models only on the larger data sets.The proprietary MOE descriptors outperformed the open-source Mordred descriptors for both random forest and neural networks. Among neural network representations, graph convolutions outperformed ECFP.A range of neural network architectures performed best, depending on the data set size. Small networks appear to be prominently featured in many data sets.Model performance generally improved as data set size increased, suggesting the need for public data set integration or multitask/transfer learning approaches.Hyperparameter tuning generally improved performance, in some cases dramatically.Uncertainty quantification showed a weak correlation with error, and the efficacy of using UQ to filter predictions varied considerably between data sets and model types.

In general, the choice of chemical representation has a strong effect on model performance. Models built on physicochemical and graph convolution descriptors tended to outperform models built on ECFP. We found that a wide sweep over a large number of hyperparameters is necessary to tune a model rather than relying on the importance of any individual hyperparameter.

The differences in prediction accuracy show that the parameters needed for *in silico* drug discovery present a diverse set of data-driven modeling challenges. The extensive benchmarking suggests that there is no clear one best modeling approach for every predicted parameter. The differences in performance show the importance of having a rigorous model building pipeline that can be readily adapted and reapplied to build parameter specific models as new data become available.

Conclusions {#sec5}
===========

In this paper, we present the ATOM Modeling PipeLine, or AMPL. This open-source software suite allows the user to build models for a wide array of molecular properties that are needed for *in silico* drug discovery. Results of extensive benchmarking on a wide variety of pharmacokinetic and safety data sets were also presented, with an exploration of the effects of different featurization and model types on model accuracy. While the data sets used for developing and testing the pipeline are not publicly available, the software used to curate data and train, evaluate, and share new models is available as open source and benefits from having been tested on a wide array of pharmaceutically relevant parameters. Additional public data sets are included with the pipeline release to support applying reproducible training and testing protocols that enable the broader modeling community to evaluate and improve modeling approaches over time.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.jcim.9b01053](https://pubs.acs.org/doi/10.1021/acs.jcim.9b01053?goto=supporting-info).PK best model parameters ([XLSX](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_001.xlsx))Benchmarking of AMPL on public datasets ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.9b01053/suppl_file/ci9b01053_si_002.pdf))
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